India's coronavirus infections ebb but states struggle for vaccines
Send a link to a friend
[May 25, 2021]
By Neha Arora and Manas Mishra
NEW DELHI (Reuters) -India's official tally
of daily infections of coronavirus fell to the lowest in nearly six
weeks in the past 24 hours, offering hope that a devastating second wave
is ebbing, but government leaders said shortages of vaccines were a big
concern.
Barely 3% of the country's 1.3 billion people have been vaccinated, the
lowest rate among the 10 countries with the most COVID-19 cases, leaving
India and its ill-equipped healthcare system vulnerable to a potential
third wave, experts say.
The Serum Institute of India, which is supplying the AstraZeneca
vaccine, and local firm Bharat Biotech which is providing Covaxin, have
both said they are ramping up production but the supply remains way
short of the millions of doses India needs.
On Tuesday, the country posted 196,427 new coronavirus cases over the
last 24 hours, its lowest daily rise in infections since April 14, and
less than half the 414,188 peak reported on May 7. The country's overall
officially recorded case load since the start of the pandemic now stands
at 26.95 million.
There are serious concerns that many new infections are not being
reported, due to a dearth of testing in the countryside, where the virus
has spread to from the cities.
Deaths due to COVID-19 amounted to 3,511 in the last 24 hours, bringing
the total since the pandemic first stuck over a year ago to 307,231,
according to health ministry data.
Experts believe that grossly underestimates the actual toll as only
people who have tested positive are counted, whereas many victims were
never tested.
The Economist magazine’s excess-deaths model estimates that around a
million people have died of COVID-19 in India so far, way above the
590,240 in the United States, which is the worst hit country based on
official counts.
DRUGMAKERS REBUFF STATES
In desperation, several Indian state governments and even cities such as
Mumbai have launched global tenders or sought expressions of interest
from firms such as Pfizer , Moderna and Johnson and Johnson for urgent
supplies.
[to top of second column]
|
Patients suffering from coronavirus disease (COVID-19) receive
oxygen support as they sit inside a classroom turned COVID-19 care
facility on the outskirts of Mumbai, India, May 24, 2021.
REUTERS/Francis Mascarenhas
But Delhi's deputy chief minister Manish Sisodia said
the three firms told them they were in touch with the federal Indian
government and that they will not be dealing with state level
authorities.
Sisodia blamed Prime Minister Narendra Modi's government for
mishandling vaccine procurement and not moving fast enough to secure
supplies for the country.
"It is a global blunder," said Sisodia, whose Aam Aadmi Party is
bitterly opposed to Modi's Bharatiya Janata Party (BJP).
The northern state of Punjab also said over the weekend its efforts
to directly source supplies had been rebuffed by the foreign vaccine
manufacturers. The hill state of Uttarakhand extended its global
tender till the end of the month after failing to get any bid, local
media reported on Tuesday.
"The vaccination drive is in shambles and people are suffering and
despairing," Anand Sharma, a leader of the main opposition Congress
said, urging Modi to put aside politics and work with state
governments to help them procure vaccines.
Pfizer said it was in talks with the Indian government to supply
its vaccine, which has still to be cleared by India's drug
regulator.
"Pfizer remains committed to continuing our engagement with the
government of India towards making the Pfizer BioNTech COVID-19
vaccine available for use in the country," a spokeswoman told
Reuters, declining to provide details of the ongoing discussions.
(Additional reporting by Tanvi Mehta in Delhi, Anuron Kumar Mitra
in Bengaluru; Writing by Sanjeev Miglani; Editing by Simon
Cameron-Moore)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|